Tissue Regenix Financials
| TRX Stock | 58.50 0.00 0.00% |
Tissue | Select Account or Indicator |
Please note, the presentation of Tissue Regenix's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Tissue Regenix's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Tissue Regenix's management manipulating its earnings.
Tissue Regenix Stock Summary
Tissue Regenix competes with DXC Technology, International Biotechnology, Alfa Financial, Xeros Technology, and CleanTech Lithium. Tissue Regenix is entity of United Kingdom. It is traded as Stock on LSE exchange.| Foreign Associate | USA |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Instrument | UK Stock View All |
| Exchange | London Exchange |
| ISIN | GB00B5SGVL29 |
| Business Address | Phoenix Court, Garforth, |
| Sector | Biotechnology |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | www.tissueregenix.com |
| Phone | 44 33 0430 3052 |
You should never invest in Tissue Regenix without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Tissue Stock, because this is throwing your money away. Analyzing the key information contained in Tissue Regenix's financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.
Tissue Regenix Key Financial Ratios
There are many critical financial ratios that Tissue Regenix's investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that Tissue Regenix Group reports annually and quarterly.| Revenue | 29.49 M | ||||
| Gross Profit | 15.73 M | ||||
| EBITDA | 446 K | ||||
| Net Income | (1.67 M) | ||||
| Total Asset | 43.24 M |
Tissue Regenix Key Balance Sheet Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Total Assets | 36.7M | 34.1M | 38.3M | 43.2M | 49.7M | 30.2M | |
| Total Liab | 8.9M | 9.5M | 13.0M | 13.9M | 16.0M | 16.8M | |
| Common Stock | 11.7M | 11.8M | 13.3M | 91K | 104.7K | 99.4K | |
| Other Current Liab | 1.4M | 477.5K | 4.4M | 2.6M | 3.0M | 1.6M | |
| Net Debt | (4.2M) | 175.7K | 3.0M | 4.7M | 5.5M | 5.7M | |
| Retained Earnings | (77.7M) | (84.7M) | (96.8M) | (123.8M) | (111.4M) | (105.8M) | |
| Accounts Payable | 1.3M | 2.6M | 1.1M | 1.2M | 1.4M | 921.0K | |
| Cash | 9.6M | 5.7M | 4.9M | 4.7M | 4.2M | 4.0M | |
| Net Receivables | 3.5M | 3.4M | 4.3M | 2.4M | 2.7M | 2.1M | |
| Good Will | 8.6M | 8.6M | 9.6M | 11.6M | 10.4M | 9.1M | |
| Other Current Assets | 1.7M | 1.2M | 834.7K | 4.1M | 4.7M | 4.9M | |
| Total Current Assets | 20.1M | 16.3M | 18.3M | 19.1M | 22.0M | 20.8M | |
| Intangible Assets | 10.9M | 11.1M | 12.5M | 3.5M | 4.1M | 3.9M | |
| Net Tangible Assets | 7.2M | 17.7M | 19.3M | 17.6M | 20.2M | 17.7M | |
| Inventory | 7.1M | 7.2M | 9.0M | 10.4M | 11.9M | 12.5M | |
| Other Liab | 670K | 560K | 640K | 520K | 468K | 618.7K | |
| Net Invested Capital | 31.3M | 38.8M | 37.5M | 36.1M | 41.6M | 38.4M | |
| Net Working Capital | 16.8M | 17.7M | 15.4M | 14.4M | 16.5M | 15.8M | |
| Capital Stock | 9.6M | 9.2M | 9.2M | 91K | 81.9K | 77.8K | |
| Long Term Debt | 2.8M | 4.5M | 5.3M | 5.5M | 6.4M | 4.4M |
Tissue Regenix Key Income Statement Accounts
An income statement is very similar to a cash flow statement, but instead of showing net revenue minus expenses, it only includes earnings before interest and taxes (EBIT). This number does not have all of the same line items that are on a cash flow statement, but it leaves out non-cash expenses like depreciation and amortization. For example, if you bought $100 worth of goods from Walmart (WMT) using your debit card that has an interest rate of 20%, then paid off the balance at the end of the month with a credit card that charges 30% interest, you would have an income statement showing EBIT of $80 because your expenses are lower than the amount that went into your pocket.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Interest Expense | 445K | 503.2K | 670.6K | 1.1M | 1.0M | 1.0M | |
| Total Revenue | 12.8M | 14.4M | 19.9M | 29.5M | 33.9M | 35.6M | |
| Gross Profit | 5.1M | 5.6M | 9.1M | 14.0M | 16.1M | 17.0M | |
| Operating Income | (4.1M) | (3.0M) | (1.6M) | (394K) | (453.1K) | (475.8K) | |
| Ebit | (9.8M) | (3.0M) | (1.6M) | (531K) | (477.9K) | (501.8K) | |
| Ebitda | (9.0M) | (2.2M) | (690.9K) | 446K | 401.4K | 421.5K | |
| Income Before Tax | (10.2M) | (3.7M) | (2.3M) | (1.3M) | (1.2M) | (1.3M) | |
| Net Income | (9.7M) | (3.5M) | (2.2M) | (1.7M) | (1.5M) | (1.6M) | |
| Income Tax Expense | (533K) | (114.2K) | (188.3K) | (12K) | (10.8K) | (11.3K) | |
| Cost Of Revenue | 7.7M | 8.7M | 10.7M | 15.5M | 17.8M | 18.7M | |
| Minority Interest | (614K) | 193K | (99K) | (56K) | (50.4K) | (52.9K) | |
| Tax Provision | (533K) | (157K) | (232K) | (12K) | (13.8K) | (14.5K) | |
| Interest Income | 2K | 3K | 8K | 26K | 23.4K | 28.9K | |
| Net Interest Income | (443K) | (689K) | (818K) | (1.3M) | (1.1M) | (1.1M) |
Tissue Regenix Key Cash Accounts
Cash flow analysis captures how much money flows into and out of Tissue Regenix Group. It measures of how well Tissue is doing because it can show the actual money that comes into and out of the Company from sales instead of measuring expenses against revenue to determine earnings. You have to read the cash flow statement in three sections. The first section shows how much money Tissue Regenix brought in, usually known as net revenue or sales. This is different from earnings because it does not include expenses when determining net revenue for use on this part of the cash flow statement. Next, are operating activities, which show how much money Tissue had leftover after paying for its expenses. This number can be calculated in two ways: by subtracting the total of all operating expenses from net revenue or by adding up changes to cash and other assets or liabilities on this part of the statement. The third section is about investing activities, which shows what Tissue Regenix has done with the money that it received from the sale of assets or what it spent to acquire new ones. This section can be broken down into two parts: investing in existing businesses (in other words, buying more stock) and investing in non-business activities like paying off debt or making acquisitions.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Change In Cash | 7.2M | (3.9M) | (746.1K) | (1.3M) | (1.2M) | (1.1M) | |
| Free Cash Flow | (6.8M) | (3.9M) | (2.3M) | 177K | 159.3K | 167.3K | |
| Depreciation | 762K | 793.3K | 921.4K | 786.0K | 903.9K | 502.5K | |
| Capital Expenditures | 1.4M | 1.5M | 884.9K | 863K | 992.5K | 569.6K | |
| Net Income | (9.7M) | (3.5M) | (2.2M) | (1.7M) | (1.5M) | (1.6M) | |
| End Period Cash Flow | 9.6M | 5.7M | 4.9M | 4.7M | 4.2M | 4.0M | |
| Other Non Cash Items | 10.9M | 2.5M | 2.7M | 1.8M | 2.1M | 2.3M | |
| Change To Inventory | (2.9M) | (83.6K) | (944.2K) | 411.0K | 369.9K | 388.4K | |
| Change To Netincome | 1.6M | 6.7M | 1.1M | 797K | 916.6K | 992.5K | |
| Investments | (1.4M) | (2.0M) | (1.1M) | (837K) | (962.6K) | (1.0M) |
Tissue Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Tissue Regenix's current stock value. Our valuation model uses many indicators to compare Tissue Regenix value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Tissue Regenix competition to find correlations between indicators driving Tissue Regenix's intrinsic value. More Info.Tissue Regenix Group is currently regarded as top stock in return on equity category among its peers. It also is currently regarded as top stock in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Tissue Regenix's earnings, one of the primary drivers of an investment's value.Tissue Regenix Group Systematic Risk
Tissue Regenix's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Tissue Regenix volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was thirty-six with a total number of output elements of twenty-five. The Beta measures systematic risk based on how returns on Tissue Regenix Group correlated with the market. If Beta is less than 0 Tissue Regenix generally moves in the opposite direction as compared to the market. If Tissue Regenix Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Tissue Regenix Group is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Tissue Regenix is generally in the same direction as the market. If Beta > 1 Tissue Regenix moves generally in the same direction as, but more than the movement of the benchmark.
Tissue Regenix Group Total Assets Over Time
Tissue Regenix January 20, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Tissue Regenix help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Tissue Regenix Group. We use our internally-developed statistical techniques to arrive at the intrinsic value of Tissue Regenix Group based on widely used predictive technical indicators. In general, we focus on analyzing Tissue Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Tissue Regenix's daily price indicators and compare them against related drivers.
| Downside Deviation | 2.01 | |||
| Information Ratio | 0.0675 | |||
| Maximum Drawdown | 9.71 | |||
| Value At Risk | (1.85) | |||
| Potential Upside | 3.45 |
Complementary Tools for Tissue Stock analysis
When running Tissue Regenix's price analysis, check to measure Tissue Regenix's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tissue Regenix is operating at the current time. Most of Tissue Regenix's value examination focuses on studying past and present price action to predict the probability of Tissue Regenix's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tissue Regenix's price. Additionally, you may evaluate how the addition of Tissue Regenix to your portfolios can decrease your overall portfolio volatility.
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Stocks Directory Find actively traded stocks across global markets |